VTVT
$36.70
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an o...
Recent News
vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin Advancements
vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the best hot stocks to buy according to analysts. On March 10, vTv Therapeutics reported its financial results for Q4 and the full-year 2025. For 2025, the company reported a net loss of $27.0 million, with R&D expenses rising to $17.9 million due to increased investment in clinical […]
Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in vTv Therapeutics (VTVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
VTv Therapeutics: Q4 Earnings Snapshot
On a per-share basis, the High Point, North Carolina-based company said it had a loss of 58 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 98 cents per share.
vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737
vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the most promising micro-cap stocks according to analysts. On February 2, vTv Therapeutics expanded its partnership with Newsoara Biopharma Co. Ltd., transforming a regional agreement into a global collaboration for the development of HPP737. Under the amended terms, Newsoara gains exclusive worldwide rights to develop and commercialize this […]
An Alzheimer’s Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here?
vTv Therapeutics (VTVT) is a $156 million biopharma focused on small molecule drugs for Alzheimer’s, diabetes, and inflammatory disorders, all in clinical trials. VTVT has surged 182% over the past year, hitting a two-year high, with strong technical momentum. Wall Street leans “Strong Buy” with targets up to $47, but...